Adani Energy Solutions has reported a significant upturn in its financial performance for the fourth quarter of the fiscal year 2024-25, driven by robust growth across its core segments. The share price closed at ₹963, with an increase of 2.6% on 24th April, 2025.
For the January-March 2025 period, Adani Energy Solutions' consolidated net profit experienced a 79% year-on-year increase, reaching ₹647.15 crore, compared to ₹361.44 crore in the corresponding quarter of the previous year. This sharp rise underscores a strong finish to the fiscal year. Revenue from operations also presented positive growth, climbing 35% year-on-year to ₹6,375 crore in the reporting quarter. This compares favourably to ₹4,720 crore in the same quarter of the prior year.
The company's operational efficiency showed improvement. Adani Energy Solutions reported an EBITDA of ₹2,250 crore for the fourth quarter of FY25, an increase from ₹1,566 crore clocked in the previous year's corresponding period. This performance contributed to an improvement in margins, which stood at 35.31%.
A closer look at the business segments reveals the drivers behind the overall growth:
Transmission Business: This segment saw its revenue increase to ₹2,247 crore in the reporting quarter, up from ₹1,647 crore a year ago.
Distribution Business: The distribution segment clocked higher revenue growth, reaching ₹2,907 crore in Q4 FY25, compared to ₹2,395 crore in the same quarter last year.
Trading Segment: The trading business saw the most dramatic growth, with revenues more than doubling to ₹378 crore from ₹114 crore in the previous year's quarter.
The robust performance in transmission, distribution, and trading segments collectively powered the substantial jump in overall revenue and profit.
The Q4 results indicate a period of significant financial strengthening for Adani Energy Solutions, marked by substantial increases in profitability and revenue across its key business verticals.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here